StonvexLoading…
StonvexStonvexStonvexCore line items from IVZ's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-20 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $1.27B | $1.74B | $6.38B | $4.69B | $3.04B |
Operating Income | Not available | $333.20M | $-695.70M | $762.40M | $491.50M |
Net Income | Not available | $219.10M | $-174.80M | $821.10M | $464.70M |
EPS (Diluted) | $0.62 | $0.51 | $-1.60 | $1.01 | $0.35 |
Total Assets | Not available | $26.83B | $27.09B | $28.44B | $28.50B |
Total Liabilities | Not available | $13.57B | $14.09B | $13.65B | $13.54B |
Cash & Equivalents | Not available | $806.90M | $1.04B | $973.10M | $922.70M |
Free Cash Flow OCF − CapEx | Not available | $198.40M | $1.44B | $1.01B | $422.40M |
Shares Outstanding | Not available | 443.30M | 444.00M | 445.10M | 446.00M |